Stockreport

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

DiaMedica Therapeutics Inc.  (DMAC) 
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm Check Earnings Report
PDF MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neuro [Read more]